Eli Lilly has shared promising results from its large-scale study comparing Mounjaro (tirzepatide) with Trulicity (dulaglutide) in adults with type 2 diabetes and heart disease. The study found that Mounjaro is at least as effective as Trulicity in preventing serious heart problems like heart attacks, strokes, and heart-related deaths. In fact, Mounjaro showed an 8% lower rate of these serious heart events and a 16% lower risk of death from any cause. The study also found that Mounjaro helped improve blood sugar levels (A1C), weight, kidney function, and other heart health markers. Kenneth Custer, a leader at Eli Lilly, said, ‘Mounjaro keeps the heart-protecting benefits of Trulicity while offering extra benefits, like better kidney protection and a lower overall risk of death.’ Over 13,000 people from 30 countries took part in this long-term study, making it the largest and longest trial of tirzepatide yet. A separate analysis suggested Mounjaro could reduce the risk of heart problems by 28% and death by 39% compared to a placebo. For people at high risk of kidney disease, Mounjaro also slowed kidney function decline by about 3.54 units over three years compared to Trulicity. Both treatments were generally safe, with stomach-related side effects being the most common. About 13.3% of Mounjaro users and 10.2% of Trulicity users stopped treatment due to side effects. Full details will be shared at a major diabetes conference in September and submitted to health regulators by the end of the year.